Non-Muscle-Invasive Bladder Cancer

San Diego, California, September 10, 2026 Tyra Biosciences, Inc. has reported initial results from the Phase 2 SURF302 clinical...

PRINCETON, N.J., July 15, 2026 UroGen Pharma announced that the U.S. Patent and Trademark Office (USPTO) has issued a...

LUND, Sweden, June 22, 2026 Hamlet BioPharma AB has announced a significant expansion of its U.S. clinical development program...